Changes in Vitamin D and Parathyroid Hormone Metabolism in Incident Pediatric Crohnʼs Disease

Department of Pediatrics, Yale-New Haven Children's Hospital, New Haven, Connecticut.
Inflammatory Bowel Diseases (Impact Factor: 5.12). 01/2013; 19(1). DOI: 10.1002/ibd.22969
Source: PubMed

ABSTRACT BACKGROUND: Prior studies of vitamin D metabolism in Crohn's disease (CD) did not include controls or examine changes following diagnosis. This study examined associations among 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)(2) D], and parathyroid hormone (PTH) levels in incident pediatric CD, compared with controls, and following diagnosis. METHODS: Serum vitamin D and PTH were measured at diagnosis (n = 78), 6, 12, and a median of 43 months (n = 52) later in CD participants, and once in 221 controls. Multivariate regression was used to examine baseline associations and quasi-least squares regression to assess subsequent changes. RESULTS: At diagnosis, 42% of CD participants were 25(OH)D-deficient (<20 ng/mL). The odds ratio for deficiency was 2.1 (95% confidence interval [CI]: 1.1, 3.9; P < 0.05) vs. controls, adjusted for age, race, and season. 1,25(OH)(2) D was lower in CD vs. controls (P < 0.05), adjusted for 25(OH)D, tumor necrosis factor alpha (TNF-α), and PTH. TNF-α was associated with lower 1,25(OH)(2) D (P < 0.05), and the positive association between PTH and 1,25(OH)(2) D in controls was absent in CD (interaction P = 0.02). Among participants with 25(OH)D <30 ng/mL, CD was associated with lower PTH (P < 0.05) vs. controls. Following diagnosis, 25(OH)D and 1,25(OH)(2) D improved (P < 0.001). At the final visit, 3% were 25(OH)D-deficient, PTH was no longer low relative to 25(OH)D, and 1,25(OH)(2) D was significantly elevated (P < 0.001) compared with controls. CONCLUSIONS: Incident CD was associated with 25(OH)D and 1,25(OH)(2) D deficiency and a relative hypoparathyroidism that resolved following diagnosis. Inflammatory cytokine suppression of PTH and renal 1-α-hyroxylase may contribute to these alterations. (Inflamm Bowel Dis 2012;).

  • [Show abstract] [Hide abstract]
    ABSTRACT: Context: Preclinical studies suggest that tumor necrosis factor-α (TNF-α) suppresses parathyroid hormone (PTH) synthesis, inhibits renal 1-α-hydroxylase activity, and impairs fibroblast growth factor 23 (FGF23) degradation. The impact of inflammation on vitamin D and mineral metabolism has not been well-characterized in Crohn's disease. Objective: To assess short-term changes in vitamin D-related mineral metabolism in CD following anti-TNF-α induction therapy. Design/participants: 87 CD participants, ages 5-39 years, were assessed at initiation of anti-TNF-α therapy and 10 weeks later. Outcomes: Indices of clinical disease activity and serum concentrations of vitamin D metabolites, vitamin D-binding protein (DBP), calcium, PTH, FGF23, interleukin (IL)-6, and TNF- α were measured at each visit. Multivariable generalized estimating equation (GEE) regression analysis was used to examine correlates of PTH and 1,25(OH)2D concentrations at each visit. Results: Following anti-TNF-α therapy, cytokine and inflammatory markers (IL-6, TNF-α, ESR and CRP) concentrations decreased (all p<0.0001), and PTH and 1,25(OH)2D concentrations increased (median 21 vs. 30 pg/ml, p<0.0001 and median 41.7 vs. 48.1 pg/ml, p=0.014, respectively). Levels of 25(OH)D, 24,25(OH)2D, DBP and FGF23 did not change. In GEE analyses, higher IL-6, TNF-α, ESR and CRP were associated with lower PTH concentrations (all p<0.001), adjusted for corrected calcium and 25(OH)D levels. Higher PTH was associated with higher 1,25(OH)2D concentrations (p<0.001) at each visit, independent of 25(OH)D concentrations. Higher levels of all inflammatory markers were associated with lower 1,25(OH)2D concentrations (all p<0.05). However, when PTH was added to these models, the inflammatory markers (with the exception of CRP) were no longer significantly associated with 1,25(OH)2D. Conclusions: Greater inflammation was associated with lower PTH and 1,25(OH)2D concentrations. Following anti-TNF-α induction, PTH and 1,25(OH)2D concentrations increased without concomitant changes in 25(OH)D and FGF23, consistent with effects of inflammation on PTH and thereby renal conversion of 25(OH)D to 1,25(OH)2D.
    The Journal of Clinical Endocrinology and Metabolism 03/2014; 99(6):jc20133846. DOI:10.1210/jc.2013-3846 · 6.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diagnostic and therapeutic recommendations of the actual guidelines regarding inflammatory bowel disease (IBD)-associated bone loss are based on the experiences from the general osteoporotic population. Moreover, the fracture, as an end point of the bone loss has a different relationship to the bone mineral density in these patients compared to the general population. In this review we aimed to review the literature of the novel therapeutic possibilities regarding IBD-related bone loss. Dual-energy X-ray absorptiometry measurement should be performed in the presence of a risk factor such as age above 50, postmenopausal state, low trauma bone fracture in the history, corticosteroid therapy for more than 3 months or signs of hypogonadism. Serum Vitamin D and calcium levels should be measured in all patients. Supplementation is definitely needed in case of low serum calcium or Vitamin D concentrations and in patients under corticosteroid induction therapy. Short-term use of bisphosphonates in case of steroid induction was proved to be efficacious in preventing bone loss, but recent approvals do not include these indications. As fluorides and hormone replacement therapy have considerable side effects, their use in the young generation is also not acceptable.
    Annals of Gastroenterology 03/2013; 26(4):296-303.
    This article is viewable in ResearchGate's enriched format
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context:Glucocorticoids and inflammation inhibit bone formation; however, the impact on skeletal modeling is unknown.Objectives:To examine changes in bone mineral density (BMD) and cortical structure after Crohn Disease (CD) diagnosis, and identify associations with growth, glucocorticoids and disease activity.Design/Participants:Prospective cohort study among 76 CD participants, ages 5-21. Tibia quantitative CT trabecular BMD and cortical dimensions were obtained at diagnosis, 6, 12 and a median of 42 months later; 51 completed the final visit.Outcomes:Sex, race and age-specific Z-scores were generated for outcomes based on >650 reference participants and cortical dimension Z-scores were further adjusted for tibia length. Generalized estimating equations were used to model changes in Z-scores.Results:Disease activity improved over the study interval (p<0.001). Trabecular BMD-Z improved over the first 6 months; increases were associated with improved disease activity (p<0.001), younger age (p=0.005), and increases in vitamin D levels (p=0.02). Greater increases in tibia length were associated with greater increases in cortical area-Z (p<0.001). Greater glucocorticoid doses and disease activity were significantly associated with failure to accrue cortical area, and were more pronounced with greater linear growth (interaction p<0.05). Mean (±SD) trabecular BMD (-1.0±1.21) and cortical area (-0.57±1.10) Z-scores at the final visit were significantly reduced.Conclusions:CD was associated with persistent deficits in trabecular BMD, although younger participants demonstrated greater potential for recovery. In addition, greater linear growth was associated with greater recovery of cortical dimensions, especially among participants with lesser glucocorticoid exposure and inflammation. These data suggest that younger age and concurrent growth provide a window of opportunity for skeletal recovery.
    The Journal of Clinical Endocrinology and Metabolism 05/2013; DOI:10.1210/jc.2013-1631 · 6.31 Impact Factor